Connect
MJA
MJA

Low dose aspirin, H. pylori infection, and the risk of upper gastrointestinal bleeding

Carlos Sostres and Angel Lanas
Med J Aust 2018; 209 (7): 297-298. || doi: 10.5694/mja18.00742
Published online: 1 October 2018

Testing patients at high risk and eradicating infection may reduce bleeding risk, but further pharmaco-economic analysis is required

Helicobacter pylori infections and low dose aspirin (75–325 mg daily) are the two most important, independently modifiable risk factors in the pathogenesis of peptic ulcers and peptic ulcer complications.1 Low dose aspirin use has increased over the past decade because of its benefits for preventing cardiovascular events and even colon cancer. Despite assertions that H. pylori infections increase the risk of aspirin-related gastrointestinal bleeding, the influence of this interaction is complex, poorly defined, and contentious. H. pylori infection is common among patients taking low dose aspirin,2 and the consequences of interactions between the two factors would therefore have important implications. A 2010 systematic review3 explored the impact of H. pylori on upper gastrointestinal bleeding risk in low dose aspirin users, but the available evidence was insufficient for strong conclusions. Of the 13 studies included in the analysis, ten were cohort studies with heterogeneous inclusion criteria, types of H. pylori, and upper gastrointestinal bleeding diagnoses, and the dosage and duration of aspirin use were also diverse; two randomised controlled trials had short follow-up periods and relatively small sample sizes.3

  • Carlos Sostres1
  • Angel Lanas2

  • 1 Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain
  • 2 Centro de Investigación Biomédica en Red (CIBER), University of Zaragoza, Zaragoza, Spain

Correspondence: alanas@unizar.es

Acknowledgements: 

This article was supported in part by a grant (FIS PI14/01218) from the Instituto de Salud Carlos III and the European Regional Development Fund of the European Union.

Competing interests:

Angel Lanas has served as an advisor to Bayer.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.